


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|--|---|
| (51) International Patent Classification ⁷ : C07D 209/08, A61K 31/404, A61P 5/36 | | A1 | (11) International Publication Number: WO 00/66554 |
| | | | (43) International Publication Date: 9 November 2000 (09.11.00) |
| (21) International Application Number: PCT/US00/11464 | | [US/US]; 546 Marview Drive, Solana Beach, CA 92075 (US). MARSCHKE, Keith, B. [US/US]; 12565 Escala Drive, San Diego, CA 92128 (US). TEGLEY, Christopher, M. [US/US]; 478 Thunderhead Street, Thousand Oaks, CA 91360 (US). | |
| (22) International Filing Date: 1 May 2000 (01.05.00) | | | |
| (30) Priority Data: 60/183,061 4 May 1999 (04.05.99) US 09/552,352 19 April 2000 (19.04.00) US | | (74) Agents: KODROFF, Cathy, A. et al.; Howson and Howson, Spring House Corporate Center, P.O. Box 457, Spring House, PA 19477 (US). | |
| (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 09/552,352 (CON) Filed on 19 April 2000 (19.04.00) | | (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (71) Applicants (for all designated States except US): AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07840 (US). LIGAND PHARMACEUTICALS, INC. [US/US]; 10275 Science Center Drive, San Diego, CA 92121 (US). | | Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): ULLRICH, John, W. [US/US]; 62 Aspen Way, Schwenksville, PA 19473 (US). FENSOME, Andrew [GB/US]; 779 Trephanny Lane, Wayne, PA 19087 (US). ZHI, Lin [CN/US]; 7794 Roan Road, San Diego, CA 92129 (US). JONES, Todd, K. | | | |
| (54) Title: 3,3-SUBSTITUTED INDOLINE DERIVATIVES | | | |
|  <div style="text-align: center;">(I)</div> | | | |
| (57) Abstract | | | |
| <p>A compound of formula (I) and pharmaceutical compositions thereof useful as progesterone receptor antagonist wherein: R₁ and R₂ are H, OH, OAc, alkylaryl, alkylheteroaryl, 1-propynyl, optionally substituted alkyl, O(alkyl), aryl, heteroaryl; or R₁ and R₂ are joined to form a ring, a double bond to CMe₂; C(cycloalkyl), O, C(cycloether); R₃ = H, OH, NH₂, COR^A, or optionally substituted alkenyl or alkynyl; R^A = H, optionally substituted alkyl, alkoxy, aminoalkyl; R₄ = H, halo, CN, NH₂, optionally substituted alkyl, alkoxy, or aminoalkyl; R₅ = optionally substituted phenyl, a 5- or 6-membered heterocycle; a 4- or 7-substituted indole or a substituted benzothiophene.</p> | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakhstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

3,3-SUBSTITUTED INDOLINE DERIVATIVES

Field of the Invention

This invention relates to compounds which are antagonists of the progesterone
5 receptor, their preparation and utility.

Background of the Invention

Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, *Science*, **240**, 889,
10 1988). The steroid receptor family is a subset of the IR family, including progesterone receptor (PR), estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR), and mineralocorticoid receptor (MR).

The natural hormone, or ligand, for the PR is the steroid progesterone, but synthetic compounds, such as medroxyprogesterone acetate or levonorgestrel, have
15 been made which also serve as ligands. Once a ligand is present in the fluid surrounding a cell, it passes through the membrane *via* passive diffusion, and binds to the IR to create a receptor/ligand complex. This complex binds to specific gene promoters present in the cell's DNA. Once bound to the DNA the complex modulates the production of mRNA and protein encoded by that gene.


20 A compound that binds to an IR and mimics the action of the natural hormone is termed an agonist, whilst a compound which inhibits the effect of the hormone is an antagonist.

PR antagonists may be used in contraception. In this context they may be administered alone (Ulmann, et al, *Ann. N.Y. Acad. Sci.*, **261**, 248, 1995), in
25 combination with a PR agonist (Kekkonen, et al, *Fertility and Sterility*, **60**, 610, 1993) or in combination with a partial ER antagonist such as tamoxifen (WO 96/19997, published July 4, 1996).

PR antagonists may also be useful for the treatment of hormone dependent breast cancers (Horwitz, et al, *Horm. Cancer*, 283, pub: Birkhaeuser, Boston, Mass.,
30 ed. Vedeckis) as well as uterine and ovarian cancers. PR antagonists may also be


useful for the treatment of non-malignant chronic conditions such as fibroids (Murphy, et al, *J. Clin. Endo. Metab.*, 76, 513, 1993) and endometriosis (Kettel, et al, *Fertility and Sterility*, 56, 402, 1991). PR antagonists may further be useful in hormone replacement therapy for post menopausal patients in combination with a partial ER antagonist such as tamoxifen (U.S. Patent No. 5,719,136). PR antagonists, such as mifepristone and onapristone, have been shown to be effective in a model of hormone dependent prostate cancer, which may indicate their utility in the treatment of this condition in men (Michna, et al, *Ann. N.Y. Acad. Sci.*, 761, 224, 1995).

Jones, et al, (U.S. Patent No. 5,688,810) describe the PR antagonist
10 dihydroquinoline A.




A

Jones, et al, described the enol ether B (U.S. Patent No. 5,693,646) as a PR
ligand.






B

Jones, *et al*, described compound **C** (U.S. Patent No. 5,696,127) as a PR ligand.


**C**

5 Zhi, *et al*, described lactones **D**, **E** and **F** as PR antagonists (*J. Med. Chem.*, 41, 291, 1998).

**D****E****F**


10

Zhi, *et al*, described the ether **G** as a PR antagonist (*J. Med. Chem.*, 41, 291, 1998).

**G**


4

Combs, *et al.*, disclosed the amide **H** as a ligand for the PR (*J. Med. Chem.*, 38, 4880, 1995).

**H**


5

Perlman, *et al.*, described the vitamin D analog **I** as a PR ligand (*Tet. Letters*, 35, 2295, 1994).

**I**


10

Hamann, *et al.*, described the PR antagonist **J** (*Ann. N.Y. Acad. Sci.*, 761, 383, 1995).


**J**

5


Chen, *et al.*, described the PR antagonist **K** (Chen, *et al.*, POI-37, 16th Int. Cong. Het. Chem., Montana, 1997).

**K**

Kurihari, *et al.*, described the PR ligand **L** (*J. Antibiotics*, 50, 360, 1997).

**L**


Elliott (Smith Kline Beecham) claimed the generic indoline **M** as potential endothelin receptor antagonists (WO 94/14434). The patent does not claim indolines and lacks the appropriate 5-aryl substitution, i.e. CN and NO₂.

**M**

R_1, R_{10}, P_1 and $P_2 = \text{H, 1-8 C alkyl, Ph}$
 $n = 0$
 $R_3 = \text{H}$
 $R_2 = \text{H}$
 $R_4 = \text{Ar (substituted)}$

15

wherein: R_4 = H, Ar, R_{11} , OH, 1-5 C alkoxy (opt. substd. by OH, OMe or halogen),
 $-S(O)_q R_{11}$, $N(R_6)_2$, XR_{11} , halogen or $NHCO R_6$; $X = (CH_2)_n$, O, NR_6 or $S(O)_q$; $n = 0-6$;
 $q = 0-2$; R_6 = H or 1-4 C alkyl; R_{11} = 1-8 C alkyl, 2-8 C alkenyl or 2-8 C alkynyl (all
 optionally substituted); Ar = (i) opt. substd. phenyl or benzo-fused gp. of (a) or (b); or
 5 (ii) naphthyl, indoyl, pyridyl, thienyl, oxazolindyl, oxazolyl, thiazolyl, isothiazolyl,
 pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, thiazolidinyl, isoxazolyl,
 oxadiazolyl, thiadiazolyl, morpholinyl, piperidinyl, pyrrolyl or pyrimidyl, all opt.
 substd. by one or more R_1 or R_2 groups.



10


A = CO or $(C(R_6)_2)_m$ B = CH_2 or O

15

Description of the Invention

The compounds of this invention have been shown to act as competitive
 inhibitors of progesterone binding to the PR and act as antagonists in functional
 models, either/or *in-vitro* and *in-vivo*. These compounds may be used for
 contraception, in the treatment and/or prevention of fibroids, including uterine
 20 fibroids, endometriosis, breast, uterine, ovarian and prostate cancer, and post
 menopausal hormone replacement therapy. This invention also particularly relates to
 methods of using these compounds in the inducement of contraception and the
 treatment and/or prevention of benign and malignant neoplastic disease. Such
 diseases may include, without limitation, benign prostatic hypertrophy, carcinomas
 25 and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary,
 meningioma and other hormone-dependent tumors.

Compounds of this invention include compounds of the formula I:



I

wherein:

- 5 R_1 and R_2 are chosen independently from H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; optionally substituted aryl; heteroaryl; optionally substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl; or 3-propynyl;

or R_1 and R_2 are joined to form a ring comprising one of the following:

- 10 $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$; $-\text{CH}_2\text{CH}_2\text{CMe}_2\text{CH}_2\text{CH}_2-$; $-\text{O}(\text{CH}_2)_m\text{CH}_2-$; $\text{O}(\text{CH}_2)_p\text{O}-$;
 $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$; $-\text{CH}_2\text{CH}_2\text{N}(\text{H or alkyl})\text{CH}_2\text{CH}_2-$;

n is an integer from 0 to 5;

m is an integer from 1 to 4;

p is an integer from 1 to 4;

- 15 or R_1 and R_2 together comprise a double bond to $=\text{C}(\text{CH}_3)_2$; $=\text{C}(\text{C}_3-\text{C}_6 \text{ cycloalkyl})$, $=\text{O}$, or $=\text{C}(\text{cycloether})$, wherein cycloether is selected from tetrahydrofuranyl or hexahydropyranyl;


R_3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, alkynyl or substituted alkynyl, or COR^A ;

- 20 $R^A =$ H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

$R_4 =$ H, halogen, CN, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_1 to C_6 alkoxy, substituted C_1 to C_6 alkoxy, C_1 to C_6 aminoalkyl, or substituted C_1 to C_6 aminoalkyl;

- 25 R_5 is selected from the groups a), b) or c):

a) R_5 is a trisubstituted benzene ring containing the substituents X, Y and Z as shown below:



X is selected from halogen, OH, CN, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ thioalkyl, substituted C₁ to C₃ thioalkyl, S(O)alkyl, S(O)₂alkyl, C₁ to C₃ aminoalkyl, substituted C₁ to C₃ aminoalkyl, NO₂, C₁ to C₃ perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^B, OCOR^B, or NR^CCOR^B;

R^B is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

R^C is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl:

Y and Z are independent substituents taken from the group including H, halogen, CN, NO₂, C₁ to C₃ alkoxy, C₁ to C₃ alkyl, or C₁ to C₃ thioalkyl; or

b) R₅ is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO₂ or NR₆ and containing one or two independent substituents from the group including H, halogen, CN, NO₂ and C₁ to C₃ alkyl, C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, COR^D, or NR^ECOR^D;

R^D is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;

R^E is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;


R₆ is H or C₁ to C₃ alkyl;

or

c) R⁵ is an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from halogen, lower alkyl, CN, NO₂, lower alkoxy, or CF₃; wherein R₆ and R₇ are independently chosen

from H, methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, cyclohexyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
or pharmaceutically acceptable salt thereof.


5 A preferred set of compounds of this invention is depicted by structure II:



II

wherein:

10 R_5 is a disubstituted benzene ring containing the substituents X, and Y as shown below:




X is selected from halogen, CN, C_1 to C_3 alkoxy, C_1 to C_3 alkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5-membered heterocyclic ring containing 1 to 3 heteroatoms, or C_1 to

15 C_3 thioalkoxy;

Y is a substituent on the 4' or 5' position selected from H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_4 alkyl, or C_1 to C_3 thioalkyl;

or

R_5 is a five membered ring having the structure:



U is O, S, or NR₆,


R₆ is H, or C₁ to C₃ alkyl, or C₁ to C₄ CO₂alkyl;

X' is selected from halogen, CN, NO₂, C₁ to C₃ alkyl or C₁ to C₃ alkoxy;

Y' is selected from the group H, F, CN, NO₂ or C₁ to C₄ alkyl;

5 or

R₅ is a six-membered ring with the structure:



X¹ is N or CX²;

X² is halogen, CN or NO₂;

10 or pharmaceutically acceptable salt thereof.

The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formulas I and II, the present invention includes
15 such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.

The term "alkyl" is used herein to refer to both straight- and branched-chain saturated aliphatic hydrocarbon groups having 1 to 8 carbon atoms, preferably 1 to 6
20 carbon atoms; "alkenyl" is intended to include both straight- and branched-chain alkyl group with 1 or 2 carbon-carbon double bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms; "alkynyl" group is intended to cover both straight- and branched-chain alkyl group with at least 1 or 2 carbon-carbon triple bonds and containing 2 to 8 carbon atoms, preferably 2 to 6 carbon atoms.

25 The terms "substituted alkyl", "substituted alkenyl", and "substituted alkynyl" refer to alkyl, alkenyl, and alkynyl as just described having one or more substituents from the group including halogen, CN, OH, NO₂, amino, aryl, heterocyclic, substituted aryl, substituted heterocyclic, alkoxy, aryloxy, substituted

alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, arylthio. These substituents may be attached to any carbon of alkyl, alkenyl, or alkynyl group provided that the attachment constitutes a stable chemical moiety.

5 The term "aryl" is used herein to refer to an aromatic system which may be a single ring or multiple aromatic rings fused or linked together as such that at least one part of the fused or linked rings forms the conjugated aromatic system. The aryl groups include but not limited to phenyl, naphthyl, biphenyl, anthryl, tetrahydronaphthyl, phenanthryl.

10 The term "substituted aryl" refers to an aryl as just defined having 1 to 4 substituents from the group including halogen, CN, OH, NO₂, amino, alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio.

15 The term "heterocyclic" is used herein to describe a stable 4- to 7-membered monocyclic or a stable multicyclic heterocyclic ring which is saturated, partially unsaturated, or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group including N, O, and S atoms. The N and S atoms may be oxidized. The heterocyclic ring also includes any multicyclic ring in which any of above defined heterocyclic rings is fused to an aryl ring. The heterocyclic ring may be attached at any heteroatom or carbon atom provided the resultant structure is chemically stable. Such heterocyclic groups include, for example, tetrahydrofuran, piperidiny, piperaziny, 2-oxopiperidiny, azepiny, pyrrolidiny, imidazolyl, pyridyl, pyraziny, pyrimidiny, pyridaziny, oxazolyl, isoxazolyl, morpholiny, indolyl, quinoliny, thienyl, furyl, benzofuranyl, benzothienyl, thiamorpholiny, thiamorpholiny sulfoxide, and isoquinoliny.

25 The term "substituted heterocyclic" is used herein to describe the heterocyclic just defined having 1 to 4 substituents selected from the group which includes halogen, CN, OH, NO₂, amino, alkyl, substituted alkyl, cycloalkyl, alkenyl, substituted alkenyl, alkynyl, alkoxy, aryloxy, substituted alkyloxy, alkylcarbonyl, alkylcarboxy, alkylamino, or arylthio. The term "thioalkyl" is used herein to refer to the SR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms.

30

The term "alkoxy" refers to the OR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms. The term "aryloxy" refers to the OR group, where R is aryl or substituted aryl, as defined above. The term "alkylcarbonyl" refers to the RCO group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "alkylcarboxy" indicates the COOR group, where R is alkyl or substituted alkyl, containing 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms. The term "aminoalkyl" refers to both secondary and tertiary amines wherein the alkyl or substituted alkyl groups, containing 1 to 8 carbon atoms, which may be either the same or different and the point of attachment is on the nitrogen atom. The term "halogen" refers to Cl, Br, F, or I.

The compounds of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include, but are not limited to, the following salts with inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium in the form of esters, carbamates and other conventional "pro-drug" forms, which, when administered in such form, convert to the active moiety *in vivo*.

This invention includes pharmaceutical compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier or excipient. The invention also includes methods of treatment which comprise administering to a mammal a pharmaceutically effective amount of one or more compounds as described above as antagonists of the progesterone receptor.

The progesterone receptor antagonists of this invention, used alone or in combination, can be utilized in methods of contraception and the treatment and/or prevention of benign and malignant neoplastic disease. Specific uses of the compounds and pharmaceutical compositions of invention include the treatment and/or prevention of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast,

colon, prostate, pituitary, meningioma and other hormone-dependent tumors, particularly progesterone-related tumors. Additional uses of the present progesterone receptor antagonists include the synchronization of the estrus in livestock.

When the compounds are employed for the above utilities, they may be
5 combined with one or more pharmaceutically acceptable carriers or excipients, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from
10 about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

15 The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to
20 four times a day, or in a sustained release form. For most large mammals, the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic
25 response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

These active compounds may be administered orally as well as by
intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch,
30 lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while

liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be
5 advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.


10 These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary
15 conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and
20 must be fluid to the extent that easy syringe ability exists. It must be stable under conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof,
25 and vegetable oil.

The compounds of this invention can be prepared by the procedures outlined in the Schemes illustrated below:

Typically the compounds of this invention are prepared in a convergent manner as shown in Scheme 1, by a suitable coupling reaction. For example, a
30 palladium mediated coupling of an aryl halide with an aryl boronic acid provides the


desired bi-aryl substituted target. The choice of the aryl halide-aryl boronic acid combination is established experimentally.

Scheme 1

- 5 As outlined in **Scheme 2**, the “right side” of the compounds of this invention may be prepared by following the procedure described in Letcher, R. M. et. al., *J. Chem. Soc. Perkin Trans.*, 1: 939 – 944, 1993.

Scheme 2

10




2

As an example, the right side template, **2**, is prepared by condensing an appropriately substituted phenyl hydrazine and a suitable ketone to give the corresponding hydrazone. This material is cyclized to an imine in refluxing acetic


acid and then reduced to the desired indoline template 2. Examples 1-7 and 10-20 were prepared by this route using the appropriate ketone.

Alternatively the right side template may be prepared as outlined in Scheme 3. The commercially available oxindole is di-alkylated at C-3 by using an appropriate base and the corresponding alkyl halide to give the 3,3-dialkyl-oxindole, 8, or the spiro-cyclic oxindole 9. These oxindoles are then brominated under standard conditions and the carbonyl group is reduced to the desired methylene using a hydride mediated reduction. The timing of the aryl coupling and the reduction of the 2-position carbonyl are established experimentally.

Scheme 3



The right side templates are coupled with an appropriate aryl boronic acid using an appropriate palladium (0) catalyst, Scheme 4. For example compound 10 is coupled under standard Suzuki conditions with an appropriately substituted aryl-boronic acid to afford compound 11.

Scheme 4

The compounds of this invention, are stable semi-solids and are conveniently converted into their corresponding salts by treatment with acid. Example 1, compound 11 (R₁ = R₂ = R₃ = Me), when treated with HCl in dioxane affords the HCl salt (Example 2) as a white solid. The racemic indolines can be separated into their enantiomers by Chiral HPLC, to provide the individual enantiomers in > 98% EE.

This invention may be further understood by the following non-limiting examples.

EXAMPLE 1**2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole****5-Bromo-2,3,3-trimethyl-2,3-dihydro-1H-indole**

This compound was prepared by the procedure of Letcher, R. M. et. al., *J. Chem. Soc. Perkin Trans.*, 1: 939 – 944, 1993.

To a solution of 4-bromo-phenyl hydrazine hydrochloride (2.59g, 11.6 mmol) and 3-methyl-2-butanone (1.0 g, 11.6 mmol) in 20 mL benzene was added acetic acid (catalytic amount) and the resulting solution was refluxed with azeotropic removal of H₂O for 14 h. The reaction mixture was cooled to room temperature and concentrated. The resulting semi-solid was extracted in acetic acid and refluxed for 12 hours. The reaction mixture was cooled to room temperature and concentrated.

The semi-solid residue was extracted in ether and neutralized with K₂CO₃. The ether

layer was dried and concentrated. The resulting solid imine was dissolved in THF-MeOH (6:1), cooled to 0°C and sodium borohydride (0.5 g, 13.2 mmol) was added. The solution was allowed to warm to room temperature and stirred for 0.5 hours. The reaction mixture was poured into 15% aqueous HCl and then made basic with K₂CO₃.

5 The organic layer was separated, washed with brine, dried (Na₂SO₄), and concentrated. The crude product was purified by column chromatography (SiO₂, hexane-ethyl acetate 9:1). The product was isolated as an orange liquid (2.1 g, 75%): ¹H-NMR (CDCl₃) δ 1.03 (s, 3H), 1.15 (d, *J* = 6.6 Hz, 3H), 1.25 (s, 3H), 3.50 (q, *J* = 6.6 Hz, 1H), 3.70 (br. s, 1H), 6.45 (d, *J* = 8.7 Hz, 1H), 7.09 (m, 2H); ¹³C-NMR (CDCl₃) δ 15.10, 22.25, 26.11 (q), 43.72 (s), 65.47 (d), 110.32 (s), 110.70, 125.47, 129.75 (d), 141.48, 148.33 (s); MS (EI) *m/z* 240, 242 (M+H)⁺.

A solution of 5-bromo-2,3,3-trimethyl-2,3-dihydro-1H-indole (0.5 g, 2.1 mmol) and tetrakis-(triphenylphosphine) palladium (0.14 g, 0.12 mmol) in dimethoxyethane (10 mL) was cycled under N₂-vacuum (4x) and then stirred under 15 N₂ for 0.5 hours. To this mixture was then added 3-nitrophenylboronic acid (0.42 g, 2.5 mmol) followed by a solution of Na₂CO₃ (0.36 g, 3.4 mmol) in 5 mL water cycled under N₂-vacuum (3x). The solution was brought to reflux for 6 hours then cooled to room temperature, poured into water and extracted with EtOAc. The combined organic extracts were washed with water, brine, dried (Na₂SO₄), and evaporated. The 20 residue was purified by column chromatography (SiO₂, methylenechloride:hexane 1:3) to afford the title compound (0.48 g, 82%) as an orange semi-solid: ¹H NMR (CDCl₃) δ 1.12 (s, 3H), 1.21 (d, *J* = 6.6 Hz, 3H), 1.35 (s, 3H), 3.60 (q, *J* = 6.6 Hz, 1H), 3.9 (br s, 1H), 6.69 (d, *J* = 7.9 Hz, 1H), 7.28-7.29 (m, 2H), 7.32 (d, *J* = 1.9 Hz, 1H), 7.53 (dd, *J* = 7.9, 7.9 Hz, 1H), 7.85 (ddd, *J* = 7.9, 2.0, 2.0 Hz, 1H), 8.07 (ddd, *J* = 25 7.9, 2.0, 2.0 Hz, 1H), 8.08 (d, *J* = 7.9 Hz, 1H), 8.39 (dd, *J* = 2.0, 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 15.27, 22.54, 26.39 (q), 43.53 (s), 65.57 (d), 109.48, 120.67, 121.04, 121.10, 126.58 (d), 129.15 (s), 129.53, 132.35 (d), 140.18, 143.64, 148.78, 150.11 (s); MS (EI) *m/z* 283 (M+H)⁺.

EXAMPLE 2**2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole Hydrochloride**

A solution of 2,3,3-trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole (0.8 g, 2.79 mmol) in 20 mL of 1:1 ether:dioxane at room temperature was treated with 1.5 mL of a 4 M HCl/dioxane solution. The resulting solid was isolated by filtration and washed with hexane to afford the title compound (0.81 g, 90%) as a tan solid: m.p. 240-241 °; ¹H-NMR (CDCl₃) δ 1.37 (s, 3H), 1.51 (s, 3H), 4.01 (d, *J* = 6.5 Hz, 1H), 7.51 (s, 1H), 7.59 (d, *J* = 7.3 Hz, 1H), 7.7 (dd, *J* = 7.9, 7.9 Hz, 1H), 7.8 (d, *J* = 7.9, 7.89 (d, *J* = 7.7 Hz, 1H), 8.3 (dd, *J* = 7.9, 1.8 Hz, 1H), 8.42 (s, 1H), 11.9 (br s, 2H); ¹³C-NMR (CDCl₃) δ; MS (EI) *m/z* 283 (M+H)⁺.

EXAMPLE 3**(2-R or S)-2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole and****and****EXAMPLE 4****(2-S or R)-2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole**

A sample of racemic 2,3,3-trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole (25 mg), as prepared in example 2, was separated by a chiral preparative HPLC [column: Chiralcel OD, 4.6 X 250 mm, isocratic, 5:95 IPA:hexane, flow rate = 1 mL/min; injection volume = 5 µL; retention times: 3, 9.2 min and 4, 10.39 min.] to provide the enantiomers 3 and 4 as orange semi-solids. Chiral Analytical HPLC determined that the enantiomers had > 99 % EE. Examples 3 and 4 have spectral data identical to the racemic material, example 1 : ¹H- NMR (CDCl₃) δ 1.12 (s, 3H), 1.21 (d, *J* = 6.6 Hz, 3H), 1.35 (s, 3H), 3.60 (q, *J* = 6.6 Hz, 1H), 3.9 (br s, 1H), 6.69 (d, *J* = 7.9 Hz, 1H), 7.28-7.29 (m, 2H), 7.32 (d, *J* = 1.9 Hz, 1H), 7.53 (dd, *J* = 7.9, 7.9 Hz, 1H), 7.85 (ddd, *J* = 7.9, 2.0, 2.0 Hz, 1H), 8.07 (ddd, *J* = 7.9, 2.0, 2.0 Hz, 1H), 8.08 (d, *J* = 7.9 Hz, 1H), 8.39 (dd, *J* = 2.0, 2.0 Hz, 1H); MS (EI) *m/z* 283 (M+H)⁺.

EXAMPLE 5**2,3,3-Diethyl-2-methyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole****5-Bromo-3,3-diethyl-2-methyl-2,3-dihydro-1H-indole**

This compound was prepared according to the procedure for Example 1 using
5 4-bromo-phenyl hydrazine hydrochloride (5.9 g, 26.3 mmol) and 3-ethyl-2-pentanone
(3.0 g, 26.3 mmol). The subtitled compound (4.5 g) was obtained in 65 % yield as a
yellowish oil: ¹H-NMR (CDCl₃) δ 0.81(t, *J* = 7.4 Hz, 3H), 0.83 (t, *J* = 7.4 Hz, 3H),
1.18 (d, *J* = 6.5 Hz, 3H), 1.42 (dq, *J* = 14.0, 7.4 Hz, 1H), 1.66 (dq, *J* = 14.0, 7.4 Hz,
3H), 3.73 (q, *J* = 6.5 Hz, 1H), 6.47 (d, *J* = 8.2 Hz, 1H), 7.02 (d, *J* = 2 Hz, 1H), 7.09
10 (dd, *J* = 8.2, 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 10.46, 10.66, 17.70 (q), 26.5, 29.67 (t),
52.25 (s), 64.80 (d), 111.64 (s), 112.41, 129.07, 131.58 (d), 139.57, 151.04 (s); MS
(EI) *m/z* 268, 270 (M+H)⁺.

Using the standard coupling conditions given in Example 1 the title compound
was prepared from 5-bromo-3,3-diethyl-2-methyl-2,3-dihydro-1H-indole (0.13 g,
15 0.45 mmol), tetrakis-(triphenylphosphine) palladium (0.05 g, 0.04 mmol) in
dimethoxyethane (4 mL) with 3-nitrophenylboronic acid (0.09 g, 0.54 mmol) and
sodium carbonate (0.15 g, 4.95 mmol) in 2 mL of water. The title compound (0.09 g,
65 %) was obtained as a red brown glass: ¹H NMR (CDCl₃) δ 0.86 (dt, *J* = 4.0, 4.0
Hz, 3H), 0.88 (dt, *J* = 4.0, 4.0 Hz, 3H), 1.24 (d, *J* = 6.6 Hz, 3H), 1.5 (dq, *J* = 14.1, 7.3
20 Hz, 1H), 1.66-1.84 (m, 3H), 3.81 (q, *J* = 6.6 Hz, 1H), 6.69 (d, *J* = 8.0 Hz, 1H), 7.20
(d, *J* = 1.9 Hz, 1H), 7.32 (dd, *J* = 8.0, 1.9 Hz, 1H), 7.53 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.85
(dd, *J* = 7.9, 1.1 Hz, 1H), 8.09 (dd, *J* = 7.9, 1.1 Hz, 1H), 8.4 (dd, *J* = 1.9 Hz, 1H); ¹³C-
NMR (CDCl₃) δ 8.99, 9.14, 16.24 (q), 24.87, 28.14 (t), 50.30 (s), 63.31 (d), 109.56,
120.80, 121.22, 123.19, 126.76 (d), 128.64 (s), 129.67, 132.55 (d), 136.5, 143.92,
25 148.95, 151.07 (s); MS (EI) *m/z* 310 (M)⁺.

EXAMPLE 6**4a-Methyl-6-(3-nitro-phenyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazole****6-Bromo-4a-methyl-2,3,4,4a,9,9a-hexahydro-1H-carbazole**

This compound was prepared by the procedure of Example 1 using 4-bromo-phenyl hydrazine hydrochloride (2.0 g, 8.95 mmol) and 2-methylcyclohexanone (1.0 g, 8.95 mmol). The subtitled compound (1.5 g, 65%) was obtained as a yellow oil: ¹H NMR (CDCl₃) δ 1.26 (s, 3H), 1.38-1.46 (m, 4H), 1.56-1.68 (m, 4H), 3.4 (t, *J* = 4.4 Hz, 1H), 3.6 (br s, 1H), 6.53 (d, *J* = 8 Hz, 1H), 7.08 (d, *J* = 2.0 Hz, 1H), 7.09 (dd, *J* = 8.0, 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 21.45, 21.87 (t), 23.96 (q), 27.92, 35.32 (t), 43.56 (s), 66.65 (d), 110.73 (s), 111.88, 125.25, 129.99 (d), 142.17, 149.03 (s); MS (EI) *m/z* 268, 270 (M+H)⁺.

Using the standard coupling conditions given in Example 1, the title compound was prepared using 6-bromo-4a-methyl-2,3,4,4a,9,9a-hexahydro-1H-carbazole (1.6 g, 6.0 mmol), tetrakis(triphenylphosphine) palladium (0.4 g, 0.35 mmol) in dimethoxyethane (30 mL) with 3-nitrophenylboronic acid (1.2 g, 7.2 mmol) and sodium carbonate (1.9 g, 18 mmol) in 10 mL water. The pure product (1.2 g, 70%) was obtained as an orange foam: ¹H NMR (CDCl₃) δ 1.36 (s, 3H), 1.44-1.74 (m, 8H), 3.49 (t, *J* = 4.4 Hz, 1H), 3.83 (br s, 1H), 6.75 (d, *J* = 8.0 Hz, 1H), 7.26 (d, *J* = 1.9 Hz, 1H), 7.32 (dd, *J* = 8.0, 1.9 Hz, 1H), 7.53 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.86 (d, *J* = 7.8 Hz, 1H), 8.08 (dd, *J* = 8.0, 2.0 Hz, 1H), 8.39 (dd, *J* = 2.0, 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 21.27, 21.71 (t), 23.87 (q), 27.76, 35.29 (t), 43.06 (s), 66.46 (d), 110.41, 120.57, 120.83, 121.24, 126.55 (d), 129.26 (s), 129.68, 132.55 (d), 140.66, 143.86, 148.95, 150.51 (s); MS (EI) *m/z* 309 (M+H)⁺.

EXAMPLE 7**1,2-Dihydro-2-methyl-5-(3-nitro-phenyl)spiro[cyclohexane-1,3-[3H]indole]****5-Bromo-1,2-dihydro-2-methylspiro[cyclohexane-1,3-[3H] indole]**

Using the conditions given in Example 1 the subtitled compound was prepared from 4-bromo-phenyl hydrazine HCl (3.5 g, 15.7 mmol) and cyclohexyl methyl ketone (2.0 g, 15.7 mmol). The pure material (3.0 g, 68%) was obtained as an oil: ¹H

NMR (CDCl₃) δ 1.09 (d, *J* = 6.5 Hz, 3H), 1.25-1.73 (m, 10H), 3.45 (br s, 1H), 3.71 (q, *J* = 6.5 Hz, 1H), 6.47 (d, *J* = 8.2 Hz, 1H), 7.09, dd, *J* = 8.2, 2.0 Hz, 1H), 7.19 (d, *J* = 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 17.22 (q), 23.19, 23.44, 26.16, 30.17, 36.70 (t), 47.99 (s), 62.34 (d), 110.08 (s), 111.07, 126.83, 130.08 (d), 139.98, 148.49 (s); MS (EI) *m/z* 280, 282 (M+H)⁺.

Using the standard coupling conditions given in Example 1 the title compound was prepared from 5-bromo-1,2-dihydro-2-methylspiro[cyclohexane-1,3-[3H] indole] (0.5 g, 1.65 mmol), tetrakis(triphenylphosphine) palladium (0.08 g, 0.07 mmol) in dimethoxy-ethane (5 mL) with 3-nitrophenylboronic acid (0.33 g, 1.98 mmol) and sodium carbonate (0.53 g, 4.95 mmol) in 5 mL water. The pure material (0.35 g, 55%) was obtained as an orange brown semi-solid: ¹H NMR (CDCl₃) δ 1.16 (d, *J* = 6.4 Hz, 3H), 1.38-1.83 (m, 10H), 3.7 (br s, 1H), 3.8 (q, *J* = 6.4 Hz, 1H), 6.69 (d, *J* = 8.0 Hz, 1H), 7.31 (dd, *J* = 8.0, 1.8 Hz, 1H), 7.53 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.86 (d, *J* = 7.3 Hz, 1H), 8.09 (d, *J* = 8.0 Hz, 1H), 8.39 (dd, *J* = 1.9, 1.9 Hz, 1H); ¹³C-NMR (CDCl₃) δ 17.45 (q), 23.32, 23.70, 26.21, 30.31, 37.07 (t), 47.77 (s), 62.11 (d), 109.81, 120.78, 121.23, 122.40, 126.92 (d), 128.96 (s), 129.66, 132.51 (d), 138.63, 143.92, 148.94, 150.1 (s); MS (EI) *m/z* 322 (M)⁺.

EXAMPLE 8

3,3-Dimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole (WAY-160655)
3,3-dimethyl-1,3-dihydro-2H-indol-2-one

This compound was prepared using the general method described by A. Kende, *Synth. Commun.*, 1: 12 (1982). The crude material was purified by column chromatography (SiO₂, methylenechloride:hexane, 1:3) to afford the subtitled compound which was consistent with the reported spectral data.

The above oxindole (0.65 g, 4.03 mmol) and sodium acetate (0.334 g, 4.07 mmol) were stirred in acetic acid (5.0 mL). Bromine (0.66 g, 0.00413 mol) in acetic acid (5.0 mL) was added drop-wise to the reaction mixture. The reaction was stirred for 50 minutes, and then poured into water (10 mL). The mixture was made basic with sodium carbonate, extracted with ethyl acetate, dried (MgSO₄), filtered, and

evaporated to give 5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.89 g, 92%):
¹H NMR (DMSO-d₆) 1.21 (s, 6 H), 6.76 (d, *J* = 8.22 Hz, 1H), 7.29 (dd, *J* = 2.1, 8.2 Hz, 1H), 7.49 (d, *J* = 2.0 Hz, 1H), 10.4 (s, 1H).

To a solution of the 5-bromo-1,3-dihydro-3,3-dimethyl-2H-indol-2-one (0.9 g, 3.7 mmol) in 20 mL THF at 0 °C was added a borane-methylsulfide complex (2M in THF, 38 mL, 75 mmol). The reaction mixture was warmed to room temperature then brought to reflux for 4 hours. The mixture was cooled to room temperature and poured into H₂O/CH₂Cl₂ and washed with 5% NaHCO₃. The organic layer was washed with brine, dried (Na₂SO₄) and concentrated. The crude product was extracted in MeOH, trimethylamine N-oxide (2.0 g, 26.6 mmol) was added, and the solution was brought to reflux for 2 hours. The reaction mixture was cooled, concentrated and the crude residue purified by column chromatography (SiO₂, methylene chloride) to afford 5-bromo-3,3-dimethyl-2,3-dihydro-1H-indole (0.074 g, 87%) as a yellow oil: ¹H NMR (CDCl₃) δ 1.29 (s, 6H), 3.30 (s, 2H), 3.5 (br s, 1H), 6.49 (d, *J* = 8.8 Hz, 1H), 7.08-7.12 (m, 2H); ¹³C-NMR (CDCl₃) δ 27.69 (q), 42.21 (s), 62.01 (d), 110.38 (s), 111.09, 125.46, 130.09 (d), 141.03, 149.52 (s); MS (EI) *m/z* 225, 227 (M)⁺.

Using the standard coupling conditions given in Example 1, the title compound was prepared from 5-bromo-3,3-dimethyl-2,3-dihydro-1H-indole (0.25 g, 1.1 mmol), tetrakis(triphenylphosphine) palladium (0.08 g, 0.07 mmol) in dimethoxyethane (5 mL) with 3-nitrophenylboronic acid (0.22 g, 1.3 mmol) and sodium carbonate (0.35 g, 3.3 mmol) in 5 mL water. The title compound (0.17 g, 60%) was obtained as a brown semi-solid: ¹H NMR (CDCl₃) δ 1.38 (s, 3H), 3.40 (s, 2H), 6.72 (d, *J* = 8.0 Hz, 1H), 7.29-7.34 (m, 2H), 7.54 (dd, *J* = 8.0, 8.0 Hz, 1H), 7.86 (d, *J* = 7.8 Hz, 1H), 8.09 (dd, *J* = 8.0, 1.5 Hz, 1H), 8.40 (dd, *J* = 2.0, 2.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ 27.89 (q), 41.93 (s), 62.05 (d), 109.78, 120.87, 121.02, 121.23, 126.87 (d), 129.19 (s), 129.69, 132.52 (d), 139.64, 143.75, 148.94, 151.17 (s); MS (EI) *m/z* 268 (M)⁺.

EXAMPLE 9

5'-(3-Chlorophenyl)-1',2'-dihydrospiro[cyclohexane-1,3'-[3H]indole]
Spiro [cyclohexane-1,3'-[3H]indol]-2'-(1'H) one

5 A solution of the oxindole (25g, 190 mmol) in 800 mL of anhydrous THF was cooled to -20°C, *n*-butyllithium (2.5M in hexanes, 152 mL, 0.38 mol) slowly added, followed by the addition of N,N,N',N'-tetramethylenediamine (51 mL, 0.38 mol). After 15 minutes, 1,5-diiodopentane (174g, 0.54 mol) was added slowly and the mixture was allowed to warm to room temperature. After stirring for 16 hours
10 saturated aqueous ammonium chloride solution (1L) and ethylacetate (1L) were added. After 15 minutes, the layers were separated and the aqueous phase was extracted with ethyl acetate. The combined organic layers were extracted with hydrochloric acid (1N, 500 mL), then washed with brine, dried (MgSO₄), and concentrated to obtain an oil. The oil was triturated with hexane (200 mL) and
15 benzene (20 mL). The precipitate was collected and dried *in vacuo* to provide Spiro [cyclohexane-1,3'-[3H]indol]-2'-(1'H) one (26.3g, 69.6%) as colorless crystals: mp 110-114°; ¹H NMR (DMSO-d₆) δ 1.67 (m, 10H), 6.84 (d, 1H, *J* = 8 Hz), 6.94 (t, 1H, *J* = 8 Hz), 7.17 (t, 1H, *J* = 8 Hz), 7.44 (d, 1H, *J* = 8 Hz), 10.3 (s, 1H).

 To a solution of the above oxindole (17.6 g, 90.0 mmol) in acetic acid (300
20 mL) was added sodium acetate (8.0 g, 100.0 mmol) and bromine (14.6g, 91.0 mmol) with stirring. After 30 minutes at room temperature, the reaction mixture was partitioned between water and ethylacetate. The aqueous phase was extracted with ethylacetate. The combined organic layers were washed with water, dried (MgSO₄) and evaporated. The residue was triturated with hexane. The precipitate was
25 collected, and dried *in vacuo* to provide 5-Bromo-spiro[cyclohexane-1,3'-[3H]indol]-2'-(1'H)-one (16.5g, 67%) as off-white crystals: m.p. 196-199°; ¹H NMR (DMSO-d₆) δ 1.62 (m, 10H), 6.8 (d, 1H, *J* = 6.8 Hz), 7.36 (d, 1H, *J* = 8.2, 1.8 Hz), 7.58 (dd, 1H, *J* = 8.2, 1.8 Hz), 10.44 (s, 1H).

 Using the standard coupling conditions given in Example 1, the title
30 compound was prepared from the above bromo-oxindole (0.32 g, 1.14 mmol)

tetrakis(triphenylphosphine) palladium (0.08g, 0.07 mmol) and 3-chlorophenylboronic acid (0.21 g, 1.37 mmol), and sodium carbonate (0.36 g, 3.4 mmol) in water (3 mL). 5-(3-chlorophenyl)-spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one (0.28 g, 80%) was obtained as a yellow solid: m.p. 164-165 °; ¹H NMR (CDCl₃) δ 1.60-1.78 (m, 6H), 1.81-1.99 (m, 4H), 7.04 (d, *J* = 8.1 Hz, 1H), 7.22-7.47 (m, 4H), 7.53 (s, 1H), 7.61 (s, 1H), 9.28 (br s, 1H); ¹³C-NMR (CDCl₃) δ 20.17, 24.12, 31.92 (t), 47.22 (s), 109.21, 121.94, 124.06, 125.50, 125.79, 125.97, 126.38, 128.96 (d), 132.88, 133.59, 135.60, 139.14, 142.17, 182.89 (s); MS (EI) *m/z* 310, 312 (M-H)⁺.

To a solution of 5-(3-chlorophenyl)-spiro[cyclohexane-1,3-[3H]indol]-2(1H)-one (0.42 g, 1.4 mmol) in 20 mL THF at 0 °C is added borane-dimethylsulfide complex, (2M in THF, 14 mL, 28 mmol). The reaction mixture was warmed to room temperature then brought to reflux for 4 hours. The mixture was cooled to room temperature and poured into H₂O with CH₂Cl₂ and washed with 5% NaHCO₃. The organic layer was washed with brine, dried over Na₂SO₄ and concentrated. The crude product was extracted in MeOH and trimethylamine N-oxide (1.0 g, 9.0 mmol) was added. The solution was brought to reflux for 2 hours, the mixture was cooled, concentrated and the crude residue purified by column chromatography (SiO₂, methylene chloride) to afford the title compound (0.25 g, 63%) as a yellow oil: ¹H NMR (CDCl₃) δ 1.3-1.55 (m, 3H), 1.6-1.85 (m, 7H), 3.1 (br s, 1H), 3.5 (s, 2H), 6.6 (d, *J* = 8.0 Hz, 1H), 7.18-7.32 (m, 4H), 7.4 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.5 (s, 1H); ¹³C-NMR (CDCl₃) δ 23.65, 26.24, 37.00 (t), 46.58 (s), 57.49 (t), 109.95, 121.82, 125.07, 126.36, 126.98, 127.08, 130.29 (d), 130.64, 134.91, 139.65, 144.29, 151.09 (s); MS (EI) *m/z* 298, 300 (M+H)⁺.

25

EXAMPLE 10**3-(2',3',3'-trimethyl-2',3-dihydro-1H-indol-5'-yl) benzonitrile**

To a solution of 5-bromo-2,3,3-trimethyl-2,3-dihydro-1H-indole (2.03 g, 8.45 mmol) in dimethoxyethane (50 mL), under nitrogen was added tetrakis(triphenylphosphine)palladium (0.47 g, 0.4 mmol). After 20 minutes at room temperature, 3-formylphenylboronic acid (2.36 g, 16.4 mmol) and potassium

30

carbonate (6.80 g, 55 mmol) in water (25 mL) was added, and the mixture was heated under reflux. After 2 hours, the mixture was cooled, poured into brine and extracted with EtOAc (x 2). The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated. The residue was then subjected to column chromatography (SiO₂, EtOAc:hexane, 1:8) to afford 3-(2',3,3'-trimethyl-2',3-dihydro-1H-indol-5'-yl) benzaldehyde (0.96 g, 3.62 mmol, 43 %) as a slightly impure solid that was used without further purification: ¹H NMR (CDCl₃) δ 1.11 (s, 3H), 1.22 (d, 3H, *J* = 6.5 Hz), 1.35 (s, 3H), 3.59 (dd, 1H, *J* = 13, 7 Hz), 6.69 (d, 1H, *J* = 1 Hz), 7.25 (s, 1H), 7.32 (s, 1H), 7.55 (t, 1H, *J* = 7.6 Hz), 7.80 (d, 1H, *J* = 1 Hz), 7.82 (d, 1H, *J* = 1 Hz), 8.05 (s, 1H), 10.07 (s, 1H).

To a solution of the above compound (0.96 g, 3.62 mmol) in MeCN/H₂O (20 mL, 95:5) was added hydroxylamine hydrochloride (0.82 g, 7.25 mmol). After 1 hour, the mixture was poured into a saturated sodium hydrogen carbonate solution and extracted with EtOAc (x2). The combined organic extracts were washed with water, dried (MgSO₄) and evaporated. The residue was then dissolved in dichloromethane (20 mL) and treated with thionyl chloride (0.53 mL, 7.25 mmol). After 16 hours, the mixture was quenched with saturated sodium hydrogen carbonate solution and concentrated, partitioned between water and EtOAc, and re-extracted with EtOAc. The combined organic extracts were washed with brine, dried (MgSO₄) and evaporated. Purification by column chromatography (EtOAc: hexane, 1:8) afforded a yellow oil (0.31 g) which was dissolved in methanol (5 mL) and treated with ethereal hydrogen chloride (1M, 1.3 mL, 1.3 mmol) and evaporated. Recrystallization from MeOH/Et₂O then afforded the title compound (0.20 g, 0.60 mmol, 18 %): mp >235 °C (decomp), ¹H NMR (CDCl₃) δ 1.57 (s, 3H), 1.36 (d, 3H, *J* = 6.7 Hz), 1.40 (s, 3H), 3.72-3.76 (m, 1H), 7.30 (d, 1H, *J* = 8 Hz), 7.67 (t, 2H, *J* = 7 Hz), 7.79 - 7.84 (m, 2H), 8.03 (d, 1H, *J* = 8 Hz), (8.2, s, 1H); MS (EI) *m/z* 262 (M)⁺.

EXAMPLE 11 - Pharmacology

The biological activity for the compounds of the current invention was evaluated in the in-vitro and in-vivo assays described below. In-vitro potencies lie in

the range 0.01 nM - 10,000 nM, and in-vivo potencies in the range 1 µg/kg to 100 mg/kg.

A. In-vitro biology

The in-vitro biology is determined by (1) competitive radioligand Binding:
5 using the A-form of the human progesterone receptor with progesterone as the radioligand; (2) co-transfection assay, which provides functional activity expressed as agonist EC50 and Antagonist IC50 values; and (3) a T47D cell proliferation, which is a further functional assay which also provides agonist and antagonist data.

1. hPR Binding assay - This assay is carried out in
10 accordance with: Pathirana, C.; Stein, R.B.; Berger, T.S.; Fenical, W.; Ianiro, T.; Mais, D.E.; Torres, A.; Glodman, M.E., Nonsteroidal human progesterone receptor modulators from the marine alga cymoplia barbata, J. Steroid Biochem. Mol. Biol., 1992, 41, 733-738.

2. PRE-luciferase assay in CV-1 cells

15 The object of this assay is to determine a compound's progestational or antiprogestational potency based on its effect on PRE-luciferase reporter activity in CV-1 cells co-transfected with human PR and PRE-luciferase plasmids. The materials methods used in the assay are as follows.

a. Medium: The growth medium was as follows:
20 DMEM (BioWhittaker) containing 10% (v/v) fetal bovine serum (heat inactivated), 0.1 mM MEM non-essential amino acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL). The experimental medium was as follows: DMEM (BioWhittaker), phenol red-free, containing 10% (v/v) charcoal-stripped fetal bovine serum (heat-inactivated), 0.1 mM MEM non-essential amino
25 acids, 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Cell culture, transfection, treatment, and luciferase assay

Stock CV-1 cells are maintained in growth medium.

30 Co-transfection is done using 1.2×10^7 cells, 5 mg pLEM plasmid with hPR-B inserted

at SphI and BamHI sites, 10 mg pGL3 plasmid with two PREs upstream of the luciferase sequence, and 50 mg sonicated calf thymus DNA as carrier DNA in 250 ml. Electroporation is carried out at 260 V and 1,000 mF in a Biorad Gene Pulser II. After electroporation, cells are resuspended in growth medium and plated in 96-well plate at 40,000 cells/well in 200 μ l. Following overnight incubation, the medium is changed to experimental medium. Cells are then treated with reference or test compounds in experimental medium. Compounds are tested for antiprogesterational activity in the presence of 3 nM progesterone. Twenty-four hr. after treatment, the medium is discarded, cells are washed three times with D-PBS (GIBCO, BRL). Fifty μ l of cell lysis buffer (Promega, Madison, WI) is added to each well and the plates are shaken for 15 min in a Titer Plate Shaker (Lab Line Instrument, Inc.). Luciferase activity is measured using luciferase reagents from Promega.

c. Analysis of Results:

Each treatment consists of at least 4 replicates. Log transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC_{50} or IC_{50} values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear response analyses.

d. Reference Compounds:

Progesterone and trimegestone are reference progestins and RU486 is the reference antiprogesterin. All reference compounds are run in full dose-response curves and the EC_{50} or IC_{50} values are calculated.

Table 1. Estimated EC₅₀, standard error (SE), and 95% confidence intervals (CI) for reference progestins from three individual studies

| 5 | <u>Compound</u> | <u>Exp.</u> | <u>EC₅₀</u> | <u>SE</u> | <u>95% CI</u> | |
|----|-----------------|-------------|------------------------|-----------|---------------|--------------|
| | | | <u>(nM)</u> | | <u>lower</u> | <u>upper</u> |
| | Progesterone | 1 | 0.616 | 0.026 | 0.509 | 0.746 |
| | | 2 | 0.402 | 0.019 | 0.323 | 0.501 |
| | | 3 | 0.486 | 0.028 | 0.371 | 0.637 |
| 10 | Trimegestone | 1 | 0.0075 | 0.0002 | 0.0066 | 0.0085 |
| | | 2 | 0.0081 | 0.0003 | 0.0070 | 0.0094 |
| | | 3 | 0.0067 | 0.0003 | 0.0055 | 0.0082 |

Table 2. Estimated IC₅₀, standard error (SE), and 95% confident interval (CI) for the antiprogestin, RU486 from three individual studies

| 15 | <u>Compound</u> | <u>Exp.</u> | <u>IC 50</u> | <u>SE</u> | <u>95% CI</u> | |
|----|-----------------|-------------|--------------|-----------|---------------|--------------|
| | | | <u>(nM)</u> | | <u>lower</u> | <u>upper</u> |
| 20 | RU486 | 1 | 0.028 | 0.002 | 0.019 | 0.042 |
| | | 2 | 0.037 | 0.002 | 0.029 | 0.048 |
| | | 3 | 0.019 | 0.001 | 0.013 | 0.027 |

Progestational activity: Compounds that increase PRE-luciferase activity significantly ($p < 0.05$) compared to vehicle control are considered active.

25 Antiprogestational activity: Compounds that decrease 3 nM progesterone induced PRE-luciferase activity significantly ($p < 0.05$)

EC₅₀: Concentration of a compound that gives half-maximal increase PRE-luciferase activity (default-nM) with SE.

30 IC₅₀: Concentration of a compound that gives half-maximal decrease in 3 nM progesterone induced PRE-luciferase activity (default-nM) with SE.

3. T47D cell proliferation assay

The objective of this assay is the determination of progestational and antiprogestational potency by using a cell proliferation assay in T47D cells. A compound's effect on DNA synthesis in T47D cells is measured. The materials and methods used in this assay are as follows.

a. Growth medium: DMEM:F12 (1:1)

(GIBCO, BRL) supplemented with 10% (v/v) fetal bovine serum (not heat-inactivated), 100U/ml penicillin, 100mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

b. Treatment medium: Minimum Essential

Medium (MEM) (#51200-038GIBCO, BRL) phenol red-free supplemented with 0.5% charcoal stripped fetal bovine serum, 100U/ml penicillin, 200 mg/ml streptomycin, and 2 mM GlutaMax (GIBCO, BRL).

c. Cell culture

Stock T47 D cells are maintained in growth medium. For BrdU incorporation assay, cells are plated in 96-well plates (Falcon, Becton Dickinson Labware) at 10,000 cells/well in growth medium. After overnight incubation, the medium is changed to treatment medium and cells are cultured for an additional 24 hr before treatment. Stock compounds are dissolved in appropriate vehicle (100% ethanol or 50% ethanol/50% DMSO), subsequently diluted in treatment medium and added to the cells. Progestin and antiprogestin reference compounds are run in full dose-response curves. The final concentration of vehicle is 0.1%. In control wells, cells receive vehicle only. Antiprogestins are tested in the presence of 0.03 nM trimegestone, the reference progestin agonist. Twenty-four hours after treatment, the medium is discarded and cells are labeled with 10 mM BrdU (Amersham Life Science, Arlington Heights, IL) in treatment medium for 4 hr.

d. Cell Proliferation Assay

At the end of BrdU labeling, the medium is removed and BrdU incorporation is measured using a cell proliferation ELISA kit (#RPN 250, Amersham Life Science) according to manufacturer's instructions. Briefly, cells are fixed in an

ethanol containing fixative for 30 min, followed by incubation in a blocking buffer for 30 min to reduce background. Peroxidase-labeled anti-BrdU antibody is added to the wells and incubated for 60 min. The cells are rinsed three times with PBS and incubated with 3,3',5,5'-tetramethylbenzidine (TMB) substrate for 10-20 min

- 5 depending upon the potency of tested compounds. Then 25 μ l of 1 M sulfuric acid is added to each well to stop color reaction and optical density is read in a plate reader at 450 nm within 5 min.

e. Analysis of Results:

- 10 Square root-transformed data are used for analysis of variance and nonlinear dose response curve fitting for both agonist and antagonist modes. Huber weighting is used to downweight the effects of outliers. EC_{50} or IC_{50} values are calculated from the retransformed values. JMP software (SAS Institute, Inc.) is used for both one-way analysis of variance and non-linear dose response analyses in both single dose and dose response studies.

- 15 f. Reference Compounds:

Trimegestone and medroxyprogesterone acetate (MPA) are reference progestins and RU486 is the reference antiprogesterin. All reference compounds are run in full dose-response curves and the EC_{50} or IC_{50} values are calculated.

- 20 **Table 3. Estimated EC_{50} , standard error (SE), and 95% confidence intervals (CI) for individual studies**

| | <u>Compound</u> | <u>Exp</u> | <u>EC_{50}</u> <u>(nM)</u> | <u>SE</u> | <u>95% CI</u> | |
|----|-----------------|------------|--|-----------|---------------|--------------|
| | | | | | <u>lower</u> | <u>upper</u> |
| 25 | Trimegestone | 1 | 0.017 | 0.003 | 0.007 | 0.040 |
| | | 2 | 0.014 | 0.001 | 0.011 | 0.017 |
| | | 3 | 0.019 | 0.001 | 0.016 | 0.024 |
| 30 | MPA | 1 | 0.019 | 0.001 | 0.013 | 0.027 |
| | | 2 | 0.017 | 0.001 | 0.011 | 0.024 |

Table 4. Estimated IC₅₀, standard error, and 95% confident interval for the antiprogesterin, RU486

| 5 | Compound | Exp | IC ₅₀ (nM) | SE | 95% CI | |
|---|----------|-----|--------------------------|-------|--------|-------|
| | | | | | lower | upper |
| | RU486 | 1 | 0.011 | 0.001 | 0.008 | 0.014 |
| | | 2 | 0.016 | 0.001 | 0.014 | 0.020 |
| | | 3 | 0.018 | 0.001 | 0.014 | 0.022 |


- 10 EC₅₀: Concentration of a compound that gives half-maximal increase in BrdU incorporation with SE; IC₅₀: Concentration of a compound that gives half-maximal decrease in 0.1 trimegestone induced BrdU incorporation with SE.

All above-noted published references are incorporated herein by reference.

- 15 Numerous modification and variations of the present invention are included in the above-identified specification are expected to be obvious to one of skill in the art. Such modifications and alterations to the methods, solutions, apparatuses of the present invention are believed to be encompassed in the scope of the claims appended hereto.

What is Claimed:

1. A compound of the formula:

**I**

wherein:

R_1 and R_2 are chosen independently from H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; optionally substituted aryl; heteroaryl; optionally substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl; or 3-propynyl;

or R_1 and R_2 are joined to form a ring comprising $-\text{CH}_2(\text{CH}_2)_n\text{CH}_2-$; $-\text{CH}_2\text{CH}_2\text{CMe}_2\text{CH}_2\text{CH}_2-$; $-\text{O}(\text{CH}_2)_m\text{CH}_2-$; $\text{O}(\text{CH}_2)_p\text{O}-$; $-\text{CH}_2\text{CH}_2\text{OCH}_2\text{CH}_2-$; $-\text{CH}_2\text{CH}_2\text{N}(\text{alkyl})\text{CH}_2\text{CH}_2-$, or $-\text{CH}_2\text{CH}_2\text{NHCH}_2\text{CH}_2-$;

n is an integer from 0 to 5;

m is an integer from 1 to 4;

p is an integer from 1 to 4;

or R_1 and R_2 together comprise a double bond to $=\text{C}(\text{CH}_3)_2$; $=\text{C}(\text{C}_3\text{-C}_6\text{ cycloalkyl})$, $=\text{O}$, or $=\text{C}(\text{cycloether})$, wherein cycloether is selected from tetrahydrofuran or hexahydropyran;


R_3 is H, OH, NH_2 , C_1 to C_6 alkyl, substituted C_1 to C_6 alkyl, C_3 to C_6 alkenyl, alkynyl or substituted alkynyl, or COR^A ;

$R^A =$ H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

$R_4 = \text{H, halogen, CN, NH}_2, \text{C}_1 \text{ to C}_6 \text{ alkyl, substituted C}_1 \text{ to C}_6 \text{ alkyl, C}_1 \text{ to C}_6 \text{ alkoxy, substituted C}_1 \text{ to C}_6 \text{ alkoxy, C}_1 \text{ to C}_6 \text{ aminoalkyl, or substituted C}_1 \text{ to C}_6 \text{ aminoalkyl};$

R_5 is selected from the groups a), b) or c):

a) R_5 is a benzene ring of the formula:



X is selected from halogen, OH, CN, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 thioalkyl, substituted C_1 to C_3 thioalkyl, S(O)alkyl , $\text{S(O)}_2\text{alkyl}$, C_1 to C_3 aminoalkyl, substituted C_1 to C_3 aminoalkyl, NO_2 , C_1 to C_3 perfluoroalkyl, 5 or 6 membered heterocyclic ring containing 1 to 3 heteroatoms, COR^B , OCOR^B , or NR^CCOR^B ;

R^B is H, C_1 to C_3 alkyl, substituted C_1 to C_3 alkyl, aryl, substituted aryl, C_1 to C_3 alkoxy, substituted C_1 to C_3 alkoxy, C_1 to C_3 aminoalkyl, or substituted C_1 to C_3 aminoalkyl;

R^C is H, C_1 to C_3 alkyl, or substituted C_1 to C_3 alkyl:

Y and Z are independently selected from H, halogen, CN, NO_2 , C_1 to C_3 alkoxy, C_1 to C_3 alkyl, or C_1 to C_3 thioalkyl;

or

b) R_5 is a five or six membered ring with 1, 2, or 3 heteroatoms from the group including O, S, SO, SO_2 or NR_6 and containing one or two independent

substituents from the group including H, halogen, CN, NO₂ and C₁ to C₃ alkyl, C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, COR^D, or NR^ECOR^D;

R^D is H, C₁ to C₃ alkyl, substituted C₁ to C₃ alkyl, aryl, substituted aryl, C₁ to C₃ alkoxy, substituted C₁ to C₃ alkoxy, C₁ to C₃ aminoalkyl, or substituted C₁ to C₃ aminoalkyl;


R^E is H, C₁ to C₃ alkyl, or substituted C₁ to C₃ alkyl;

R₆ is H or C₁ to C₃ alkyl;

or

c) R⁵ is an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety, the moiety being optionally substituted by from 1 to 3 substituents selected from halogen, lower alkyl, CN, NO₂, lower alkoxy, or CF₃; wherein R₆ and R₇ are independently chosen from H, methyl, ethyl, propyl, butyl, iso-propyl, iso-butyl, cyclohexyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
or pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 having the formula:



wherein:


X is selected from halogen, CN, C₁ to C₃ alkoxy, C₁ to C₃ alkyl, NO₂, C₁ to C₃ perfluoroalkyl, 5-membered heterocyclic ring containing 1 to 3 heteroatoms, or C₁ to C₃ thioalkoxy;

Y is a substituent on the 4' or 5' position selected from H, halogen, CN, NO₂, C₁ to C₃ alkoxy, C₁ to C₄ alkyl, or C₁ to C₃ thioalkyl;

or pharmaceutically acceptable salt thereof.

3. A compound of Claim 2 wherein X is CN or NO₂ and Y is 5'-fluoro; or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 1 having the formula:



wherein:

U is O, S, or NR₆,


R₆ is H, or C₁ to C₃ alkyl, or C₁ to C₄ CO₂alkyl;

X' is selected from halogen, CN, NO₂, C₁ to C₃ alkyl or C₁ to C₃ alkoxy;

Y' is selected from the group H, F, CN, NO₂ or C₁ to C₄ alkyl;


or pharmaceutically acceptable salt thereof.

5. A compound of Claim 4 having the formula:




wherein Y' is H or alkyl; or a pharmaceutically acceptable salt thereof.

6. A compound of Claim 4 which has the formula:



or a pharmaceutically acceptable salt thereof.

7. A compound of Claim 1 having the formula:



wherein:

X¹ is N or CX²;

X² is halogen, CN or NO₂;
or pharmaceutically acceptable salt thereof.

8. A compound of Claim 1 which is 2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole or a pharmaceutically acceptable salt thereof.

9. A compound of Claim 1 which is 2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole Hydrochloride or a pharmaceutically acceptable salt thereof.

10. A compound of Claim 1 which is (2-R)-2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole or a pharmaceutically acceptable salt thereof.

11. A compound of Claim 1 which is (2-S)-2,3,3-Trimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole or a pharmaceutically acceptable salt thereof.

12. A compound of Claim 1 which is 2,3,3-Diethyl-2-methyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole or a pharmaceutically acceptable salt thereof.

13. A compound of Claim 1 which is 4a-Methyl-6-(3-nitro-phenyl)-2,3,4,4a,9,9a-hexahydro-1H-carbazole or a pharmaceutically acceptable salt thereof.

14. A compound of Claim 1 which is 1,2-Dihydro-2-methyl-5-(3-nitro-phenyl)spiro[cyclohexane-1,3-[3H]indole] or a pharmaceutically acceptable salt thereof.

15. A compound of Claim 1 which is 3,3-Dimethyl-5-(3-nitro-phenyl)-2,3-dihydro-1H-indole or a pharmaceutically acceptable salt thereof.

16. A compound of Claim 1 which is 5'-(3-Chlorophenyl)-1',2'-dihydrospiro[cyclohexane-1,3'-[3H]indole] or a pharmaceutically acceptable salt thereof.
17. A compound of Claim 1 which is 3-(2',3',3'-trimethyl-2',3-dihydro-1H-indol-5'-yl) benzonitrile or a pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier or excipient.
19. A method of inducing contraception in a mammal, the method comprising administering to the mammal a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.
20. A method of treating or preventing benign or malignant neoplastic disease in a mammal, the method comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.
21. The method of Claim 19 wherein the benign or malignant neoplastic disease is selected from the group of uterine myometrial fibroids, endometriosis, benign prostatic hypertrophy; carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, meningioma or other hormone-dependent tumors.

INTERNATIONAL SEARCH REPORT

| | | | | |
|--|---|--|---|---|
| A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07D209/08 A61K31/404 A61P5/36 | | International Application No PCT/US 00/11464 | | |
| According to International Patent Classification (IPC) or to both national classification and IPC | | | | |
| B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07D | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched | | | | |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used) CHEM ABS Data, EPO-Internal | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | |
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | |
| A | WO 98 27059 A (MEIJI SEIKA KAISHA LTD) 25 June 1998 (1998-06-25) claim 1 | 1,18 | | |
| P,A | & EP 0 947 507 A 6 October 1999 (1999-10-06) page 59 -page 70 | | | |
| A | WO 94 14434 A (SMITHKLINE BEECHAM CORPORATION) 7 July 1994 (1994-07-07) cited in the application page 4 -page 8, line 25 | 1,18 | | |
| A | EP 0 535 529 A (NISSHIN FLOUR MILLING CO., LTD) 7 April 1993 (1993-04-07) page 3 -page 5 | 1,18 | | |
| -/- | | | | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. | | | | |
| * Special categories of cited documents : | | | | |
| <table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Δ* document member of the same patent family </td> </tr> </table> | | | *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Δ* document member of the same patent family |
| *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Δ* document member of the same patent family | | | |
| Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">7 September 2000</div> | | Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">14/09/2000</div> | | |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 | | Authorized officer <div style="text-align: center; font-weight: bold;">Kyriakakou, G</div> | | |

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/11464

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | US 5 688 810 A (TODD K. JONES ET AL.) 18 November 1997 (1997-11-18) cited in the application column 1 -column 22, line 42 | 1,18 |
| A | US 5 696 127 A (TODD K. JONES ET AL.) 9 December 1997 (1997-12-09) cited in the application column 1 -column 22 | 1,18 |
| A | KATO L. PERLMAN ET AL.: "20-Oxopregnacalciferols: Vitamin D compounds that bind the Progesterone Receptor" TETRAHEDRON LETTERS, vol. 35, no. 15, 1994, pages 2295-2298, XP002029720 great Britain cited in the application the whole document | 1,18 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/11464

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| WO 9827059 A | 25-06-1998 | AU 7738098 A BR 9714145 A EP 0947507 A US 6077840 A | 15-07-1998 29-02-2000 06-10-1999 20-06-2000 |
| WO 9414434 A | 07-07-1994 | AU 5873594 A CN 1096513 A EP 0676959 A JP 8504826 T MX 9400071 A ZA 9309516 A | 19-07-1994 21-12-1994 18-10-1995 28-05-1996 29-07-1994 06-06-1994 |
| EP 535529 A | 07-04-1993 | JP 5092973 A DE 69221059 D DE 69221059 T US 5252580 A | 16-04-1993 04-09-1997 13-11-1997 12-10-1993 |
| US 5688810 A | 18-11-1997 | AU 717251 B AU 4597796 A BR 9510486 A CA 2208347 A CN 1175247 A CZ 9701761 A EP 0800519 A JP 10510840 T NO 972591 A WO 9619458 A US 6093821 A HU 78117 A US 5696130 A US 5688808 A US 5693646 A US 5693647 A US 5696127 A US 5696133 A US 5994544 A | 23-03-2000 10-07-1996 02-06-1998 27-06-1996 04-03-1998 16-09-1998 15-10-1997 20-10-1998 14-08-1997 27-06-1996 25-07-2000 29-11-1999 09-12-1997 18-11-1997 02-12-1997 02-12-1997 09-12-1997 09-12-1997 30-11-1999 |
| US 5696127 A | 09-12-1997 | AU 717251 B AU 4597796 A BR 9510486 A CA 2208347 A CN 1175247 A CZ 9701761 A EP 0800519 A HU 78117 A JP 10510840 T NO 972591 A WO 9619458 A US 5696130 A US 5688808 A US 5693646 A US 5688810 A US 5693647 A US 5696133 A US 6093821 A US 5994544 A | 23-03-2000 10-07-1996 02-06-1998 27-06-1996 04-03-1998 16-09-1998 15-10-1997 29-11-1999 20-10-1998 14-08-1997 27-06-1996 09-12-1997 18-11-1997 02-12-1997 18-11-1997 02-12-1997 09-12-1997 25-07-2000 30-11-1999 |